Evidence map›Paper›PMID 35707728›Full record

ArticleiScience2022

Iloprost requires the Frizzled-9 receptor to prevent lung cancer.

Kayla Sompel, Lori D Dwyer-Nield, Alex J Smith, Alamelu Elango, Don S Backos, Bicheng Zhang, James Gross, Kristina Ternyak, Jennifer L Matsuda, Katrina Kopf and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Kayla SompelDivision of Pulmonary Sciences and Critical Care Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Lori D Dwyer-NieldSkaggs School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Alex J SmithDivision of Pulmonary Sciences and Critical Care Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Alamelu ElangoDivision of Pulmonary Sciences and Critical Care Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Don S BackosSkaggs School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Bicheng ZhangNational Jewish Health, Denver, CO, USA.
James GrossNational Jewish Health, Denver, CO, USA.
Kristina TernyakNational Jewish Health, Denver, CO, USA.
Jennifer L MatsudaNational Jewish Health, Denver, CO, USA.
Katrina KopfNational Jewish Health, Denver, CO, USA.
Robert L KeithDivision of Pulmonary Sciences and Critical Care Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Meredith A TennisDivision of Pulmonary Sciences and Critical Care Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
University of Colorado Anschutz Medical Campus · USNational Jewish Health · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Frizzled 9 loss and regulation in preventing the progression of pre-malignant lung lesionsR01CA214531 · NCI · UNIVERSITY OF COLORADO DENVER · PI TENNIS, MEREDITH A · 2017 to 2021
$1.8M
NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA214531
6 · The paper itself

Abstract

Prevention of premalignant lesion progression is a promising approach to reducing lung cancer burden in high-risk populations. Substantial preclinical and clinical evidence has demonstrated efficacy of the prostacyclin analogue iloprost for lung cancer chemoprevention. Iloprost activates peroxisome proliferator-activated receptor gamma (PPARG) to initiate chemopreventive signaling and

Indexed as

BiochemistryBiological sciencesCancer

Identifiers

PMID35707728
PMCPMC9189122
OpenAlexW4281391286

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.